Tumor-associated macrophages correlate with better outcome in SHH medulloblastoma

Jin Zhang1, Shuting Li1, Yuan Wang1

  • 1Department of Pediatrics, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Frontiers in Oncology
|April 30, 2025
PubMed
Abstract

Insights

Increased total macrophages and M2 macrophages correlate with better outcomes in sonic hedgehog medulloblastoma. Tumor-associated macrophages (TAMs), particularly M2 types, may represent a therapeutic target for this brain tumor.

Area of Science:

  • Neuro-oncology
  • Immunology
  • Pathology

Background:

  • Tumor-associated macrophages (TAMs) are key components of the tumor microenvironment (TME) in brain tumors.
  • Macrophage polarization significantly influences the TME, but their specific role in sonic hedgehog (SHH) medulloblastoma is not well-defined.

Purpose of the Study:

  • To investigate the polarization characteristics and impact of TAMs in SHH medulloblastoma.
  • To analyze the correlation between TAM infiltration and clinical outcomes in SHH medulloblastoma patients.

Main Methods:

  • Analysis of 42 SHH medulloblastoma patient samples using multiple immunofluorescence staining.
  • Detection of M1 and M2 macrophage phenotypes (CD68, HLA-DR, CD163) and correlation with clinical characteristics and prognostic factors.

Main Results:

  • Higher M_total (total macrophages) and M_mix (CD68+HLA-DR+CD163+) were observed in younger patients (<5 years).
  • M_total was higher in non-metastatic cases. M2 macrophages were more prevalent in classic medulloblastoma (CMB) compared to desmoplastic/nodular medulloblastoma (DNMB)/medulloblastoma with extensive nodularity (MBEN).
  • High M_total and M2 macrophage levels correlated with better 5-year progression-free survival (PFS) and overall survival (OS), with M2 macrophages being independent prognostic factors.

Conclusions:

  • Elevated total and M2 macrophage levels predict improved outcomes in SHH medulloblastoma.
  • TAMs, especially M2 macrophages, represent a potential therapeutic target for SHH medulloblastoma.